in vivo-jetPEI®

Molecule delivered



in vivo functional studies (overexpression, knock-down, CRISPR genome editing)
Cancer Research

Targeted organs

All organs

Injection routes

Various systemic and local administration routes

Number of transfections

eg. 100 µl of in vivo-jetPEI® delivery reagent is sufficient to perform 15 to 25 intravenous injections in mouse.


Store in vivo-jetPEI® at -20 ± 5 °C.
Expiry date is indicated in the certificate of analysis (available in "My account") and on the product.

Provided with

10% glucose solution


in vivo-jetPEI® is the most advanced in vivo transfection reagent for safe and efficient in vivo delivery of DNA, si/miRNA and other oligonucleotides in animal models. With a track record of over 700 publications, in vivo-jetPEI® is the consensual in vivo transfection method for in vivo functional studies, cancer research and immunization/vaccination.

Table 1: Range of in vivo-jetPEI® quality grade reagents for each step of in vivo DNA, si/miRNA transfection. in vivo-jetPEI® is available as an R&D grade for fundamental research and proof of concept studies. For preclinical biodistribution and toxicology studies and early phase clinical studies, we supply a higher preclinical grade in vivo-jetPEI®. GMP in vivo-jetPEI® is the highest quality grade available to meet quality demands in Human clinical trials.

Ordering information

Reference NumberAmount of reagentAmount of 10% glucose solution
101000040in vivo-jetPEI® 0.1 mL10 ml
101000030in vivo-jetPEI® 0.5 mL2 x 10 ml

Bulk quantities and GMP grade reagent are available upon request. Please contact us.

Request a quote


Polyvalent: in vivo delivery of DNA, si/sh/miRNA nucleic acid in any animal model including mice

The easiness of use and versatility of in vivo-jetPEI® allows scientists to perform gene function studies by overexpressing or downregulating a gene in any organ/tissue of interest. in vivo-jetPEI® is polyvalent: it is suitable for the delivery of nucleic acid (plasmid DNA, siRNA, shRNA, miRNA and oligonucleotides) in any animal model (mice, rat, guinea pig, dog, rabbit, monkey, etc…). Numerous Scientific publications demonstrate the successful delivery of each type of nucleic acid in different animal model.

in vivo-jetPEI® has already been used to target a wide range of organs by systemic and local injection routes. Local administration routes include subcutaneous tumor, intracerebral or intra-articular injections and topical application. The injection route largely determines the targeted organs. For example, upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery. Conversely, upon intraperitoneal injection, the gene of interest will be expressed in the ovary, pancreas, diaphragm, uterus and stomach (Fig. 1). To achieve organ specific gene expression, cell-specific promoters can be combined with the choice of a local injection route to restrict gene expression to an organ/tissue. Guidelines for systemic and most local injection routes are available.

<em>in vivo</em>-jetPEI - Intravenous injection & intraperitoneal injection in mice

Fig. 1: Organs targeted following systemic nucleic acid delivery using in vivo-jetPEI® in mice. Complexes were formed using 40 μg or 100 μg of luciferase expressing plasmid and in vivo-jetPEI® at an N/P ratio of 8, in 200 μl or 1 ml of 5% glucose and injected either through retro-orbital sinus (IV) or intraperitoneally (IP), respectively. 24 hours after injection, different organs were extracted and luciferase expression was measured or live imaging was performed using IVIS system (Perkin Elmer).


Easy-to-use: two-step protocol

 in vivo-jetPEI® is the reagent of choice to deliver DNA, si/sh/miRNA nucleic acid using most systemic and local injection routes. The protocol is easy to use and similar to a classical in vitro transfection: the nucleic acid and in vivo-jetPEI® reagent are mixed and directly injected into the animal model (Fig. 2).

<em>in vivo</em>-jetPEI - easy 2-step protocol

Fig 2: in vivo-jetPEI® protocol in mice. This two-step protocol is compatible with direct injection of in vivo-jetPEI®/nucleic acid nanoparticles though any systemic or local administration routes.

Our delivery experts are available to adapt your protocol to your animal model and send you the relevant literature.

contact the Scientific Support


Renowned: Most advanced in vivo delivery technology for cancer research, immunization and vaccination

in vivo-jetPEI® is a powerful polymer-based reagent with unique properties. In the provided complexation solution, in vivo-jetPEI® condenses any nucleic acid into stable nanoparticles of ca. 50 nm diameter (Fig 1). These nanoparticles are sufficiently small to efficiently diffuse within tissues and enter cells by endocytosis, while protecting naked nucleic acids from degradation. At the cellular level, in vivo-jetPEI facilitates both endosomal escape using the proton sponge mechanism (Akinc et al. (2005), J Gene Med 7: 657), and crossing of the nuclear membrane (Brunner et al. (2002), Mol Ther 5: 80).

<em>in vivo</em>-jetPEI - complex size

Fig. 3 in vivo-jetPEI® forms small spherical particles with plasmid DNA. in vivo-jetPEI®/DNA complexes are prepared in 5% glucose solution at N/P ratio of 10. Complexes were added on a carbon covered grid and stained with uranyl acetate. Observation was carried out under a TEM. Bar is 100 nm. Complexes produced in glucose solution are discrete spheres having a mean size of 50 +/- 30 nm (Courtesy J-S Remy, Laboratoire Chimie Génétique, CNRS UMR 7514, Illkirch, France).

Successful: Used from fundamental research to Human clinical trials

Due to its reliability, in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. There are currently several ongoing clinical trials for cancer therapies, vaccination and immunization using higher quality grade GMP in vivo-jetPEI®.


If you have any questions regarding in vivo-jetPEI®, please visit our dedicated Frequently asked questions or contact us.


in vivo functional studies

in vivo-jetPEI® is perfectly suited to study gene function in vivo and provides the easiest method for the validation of in vitro functional studies into animals.

Read more…

Cancer Therapy

in vivo-jetPEI®-based nucleic acid delivery is now widely used for tumor growth inhibition studies. As an example, the delivery of a modified siRNA against Cyclin B1 with in vivo-jetPEI® inhibits the formation of lung metastases (Fig. 4A) and in vivo-jetPEI® mediated delivery of a modified siRNA against Survivin prevents the growth of a tumor xenograft model (Fig. 4B).

<em>in vivo</em>-jetPEI - Cancer therapy

Fig. 4: Tumor growth inhibition following in vivo-jetPEI® mediated delivery of modified siRNAs. (A) Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated intravenously with 1 mg/kg of STICKY siRNA™ against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90. (B) Mice bearing tumor xenografts were treated intravenously with 1 mg/kg of STICKY siRNA™ against Survivin (N/P=12.5). Tumor growth was monitored after each treatment and represented as a mean tumor volume ± SEM. Data from Kedinger et al., (2013), BMC Cancer 13:338.

Read more…


Following in vivo administration of plasmid DNA formulated with in vivo-jetPEI®, the expressed protein can elicit the induction of a robust and persistent immune response, hence protecting animals from different viruses or pathogens challenge.

Read more…

 in vivo gene editing using CRISPR/Cas9 system

in vivo-jetPEI®-mediated delivery of CRISPR/Cas9 system targeting tumor suppressor genes provides a flexible and effective method to investigate somatic loss-of-function alterations and their influence on tumorigenesis.

📰 Download our Researcher’s guide to Genome editing!

Read more…


Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.

Each batch of in vivo-jetPEI® reagent is tested for conformity to established Quality Controls and relevant specifications. A Certificate of Analysis is provided with each vial of reagent


« I finished the experiments and I think in vivo-jetPEI® works great. I am very pleased with the results. Actually some of the work we have done with in vivo-jetPEI® as well as jetSI™ 10 mM has been published in Science. […] I am also very pleased with the technical assistance. Many thanks! »
 Emine E.K., Hacettepe University, Turkey 
« Our project is going quite well, we are working a lot with your siRNAs delivery system, and we are obtaining superb results in vivo. »
 Mattia C., L’Aquila University, Italy 
« in vivo-jetPEI® is a very nice reagent to work with! »
 Marie-Line G., Lady Davis Institute, Canada 


Order by :  
Found 566 results :
Cell Linein vitro
in vivo
Delivered MoleculeReagentResults & Citations
-in vivoDNAin vivo-jetPEI
Ansaldi, D. et al. (2011)

PLoS ONE 6, e25093
Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8
More details
-in vivoDNAin vivo-jetPEI
Bivas-Benita, M. et al. (2013)

Mucosal Immunol 6, 156-66
Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity
More details
-in vivosiRNAin vivo-jetPEI
Campbell, M. et al. (2012)

Nat Commun 3, 849
Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury
More details
-in vivomimic miRNAin vivo-jetPEI
Cubillos-Ruiz, J. R. et al. (2012)

Cancer Res 72, 1683-93
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer
More details
-in vivomodified siRNAin vivo-jetPEI
Ellermeier, J. et al. (2013)

Cancer Res 73, 1709-20
Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer
More details
-in vivoshRNA plasmidin vivo-jetPEI
George, J. et al. (2007)

Gene Ther 14, 790-803
siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats
More details
-in vivooligonucleotide, shRNA oligonucleotidein vivo-jetPEI
Hu, G. H. et al. (2014)

Int J Clin Exp Pathol 7, 2143-52
Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo
More details
-in vivosiRNAin vivo-jetPEI
Jin, X. H. et al. (2014)

J Neurosci Res 92, 1690-702
P2X4 receptor in the dorsal horn partially contributes to brain-derived neurotrophic factor oversecretion and toll-like receptor-4 receptor activation associated with bone cancer pain
More details
-in vivosiRNAin vivo-jetPEI
Kim, H. Y. et al. (2014)

Febs J ,
Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion
More details
-in vivomimic miRNAin vivo-jetPEI
Kong, L. M. et al. (2014)

Cancer Res 74, 3764-78
A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis
More details